

Sunnybrook Research Institute: Fact Sheet

The main aims of Sunnybrook Research Institute (SRI) are to understand and prevent disease, and develop treatments that enhance and extend life. These aims derive from a core vision: to achieve discovery and its translation into the clinic to set best practices.

- Sunnybrook Research Institute is a fully affiliated research and teaching hospital with the University of Toronto. As of 2004/2005, we are second only to the University Health Network in external research funding among all University of Toronto-affiliated research institutes.
- In 2004/2005, scientists conducted more than \$85 million in research; in 2005/2006, that number is projected to top \$90 million.
- Research at SRI spans the spectrum of discovery from basic science to translational research to knowledge transfer and commercialization.
- There are four disciplines: molecular and cellular biology, clinical integrative biology, imaging and clinical epidemiology. Research spans two Toronto-based campuses: Sunnybrook Health Sciences Centre and the Holland Orthopaedic and Arthritic Centre.
- Each scientist aligns with a discipline and one of seven clinically focused strategic programs: aging and population health, cancer, cardiac, musculoskeletal, perinatal and gynecology, neurosciences, and trauma and critical care.
- SRI has 170 scientists and clinician-scientists. In addition, there are about 220 research associates, engineers, physicists and technicians; and 200 research fellows and graduate students, which brings the total number of research personnel at SRI to about 600.
- SRI's three largest capital projects are unique in Canada: the Breast Cancer Research Centre, the Imaging Research Centre for Cardiac Intervention, and the Toronto Angiogenesis Research Centre. Funded mainly by the Canada Foundation for Innovation and Ontario Innovation Trust, the total project value of these multidisciplinary projects is \$38.4 million.
- SRI leads three multi-institutional consortia funded by the Ontario Research Development Challenge Fund and private-sector investment: the Ontario Consortium in Cardiac Imaging, the Ontario Consortium in Small Animal Imaging and the Advanced Regenerative Tissue Engineering Centre. Together, these consortia have a project budget of \$103 million.
- SRI is active in commercializing its research. Research here has led to the formation of several spin-off companies, including VisualSonics Inc. and Sentinelle Medical Inc.
- In 2004/2005, SRI had industry-sponsored research of more than \$4 million from Amgen, Apotex Inc., Elastin Specialties, GE Healthcare, Pfizer Canada and sanofi pasteur, among many others.
- The global headquarters of sanofi pasteur's Cancer Vaccine Program is located at SRI. Sanofi pasteur, Canada's largest vaccine company, sponsors cancer vaccine research at SRI through its Cancer Vaccine Network.
- SRI was the first to register an Ontario community small business investment fund (CSBIF) with the government's CSBIF program. We have two CSBIFs: Sunnybrook Working Ventures Medical Breakthrough Fund and the Medical Ventures Fund.